• Explore /
  • Poster
  • / Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).

Abstract Poster

Authors

Eric Van Cutsem

Eric Van Cutsem

University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium

Eric Van Cutsem , Ken Kato , Jaffer A. Ajani , Lin Shen , Tianyu Xia , Ningning Ding , Lin Zhan , Gisoo Barnes , Sung-Bae Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Quality of Care/Quality Improvement

Clinical Trial Registration Number

NCT03430843

DOI

10.1200/JCO.2022.40.4_suppl.268

Abstract #

268

Poster Bd #

E10

Abstract Disclosures

Similar Posters

First Author: Kuaile Zhao

First Author: Lin Shen

First Author: Eric Raymond

First Author: John A. Bridgewater